Muscle Pharm Corp. (MSLP)


Other OTC - Other OTC Delayed Price. Currency in USD
2.170.00 (0.00%)
As of 2:00 PM EDT. Market open.
People also watch:
CDXCCOCPPGLCOPKIDI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close2.17
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market Cap30.02M
P/E Ratio (ttm)-0.62
Beta2.65
Volume0
Avg Vol (3m)13,992
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • MusclePharm Corp. :MSLP-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016
    Capital Cube9 days ago

    MusclePharm Corp. :MSLP-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016

    Categories: Yahoo Finance Get free summary analysis MusclePharm Corp. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of MusclePharm Corp. – GNC Holdings, Inc. Class A, Mylan N.V. and Bristol-Myers Squibb Company (GNC-US, MYL-US and BMY-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)

  • PR Newswire16 days ago

    MusclePharm Reports 2016 Second Quarter Financial Results

    DENVER, Aug. 9, 2016 /PRNewswire/ -- MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, ...

  • PR Newswire3 months ago

    MusclePharm Corporation Announces More Than $45 Million in Future Commitments Trimmed To Date

    DENVER, May 26, 2016 /PRNewswire/ -- MusclePharm Corporation (MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, announced a reduction of more than $45 million in future commitments to date as part the Company's ongoing restructuring program. The Company has exited a number of sponsorship and endorsement agreements resulting in an overall reduction of approximately $39.5 million in future contractual commitments and an additional $6 million of annualized headcount reduction. In the most recent reduction, the Company entered into an amicable Settlement Agreement with ETW Corp. which places MusclePharm in a stronger financial position going forward.